This clinical trial is focused on studying a type of cancer called Mantle Cell Lymphoma, which is a rare form of non-Hodgkin’s lymphoma. The study is investigating the effectiveness of a treatment combination that includes the drugs Bendamustine, Rituximab, and Acalabrutinib (also known by its code name ACP-196). The purpose of the study is to evaluate how well this combination works compared to Bendamustine and Rituximab alone, with or without a placebo.
Participants in the study will receive treatment over a period of time, during which they will be given the medications either through an intravenous method, which means the drugs are delivered directly into a vein, or orally, which means they are taken by mouth in the form of capsules. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results.
The trial aims to assess the progression-free survival of patients, which refers to the length of time during and after treatment that a patient lives with the disease without it getting worse. This assessment will be done according to specific guidelines for non-Hodgkin’s lymphoma. The study will help determine if adding Acalabrutinib to the treatment regimen provides any additional benefit to patients with previously untreated Mantle Cell Lymphoma.
Belgium 
Czechia 
France 
Germany 
Greece 
Hungary 
Italy 
Poland 
Spain 
